Hu Ming-Hung, Wang Ling-Wei, Lu Hsueh-Ju, Chu Pen-Yuan, Tai Shyh-Kuan, Lee Tsung-Lun, Chen Ming-Huang, Yang Muh-Hwa, Chang Peter Mu-Hsin
Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Division of Hematology and Oncology, Department of Medicine, Cardinal Tien Hospital, No. 362, Zhongzheng Road, New Taipei City 231, Taiwan.
Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Cancer Center, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan.
Biomed Res Int. 2014;2014:904341. doi: 10.1155/2014/904341. Epub 2014 Jul 6.
This study aimed to analyze survival, clinical responses, compliance, and adverse effects in locally advanced head and neck cancer (LAHNC) patients treated with split-dose cisplatin-based concurrent chemoradiation therapy (SD-CCRT) or cetuximab with concurrent radiation therapy (BioRT).
We retrospectively evaluated 170 LAHNC patients diagnosed between January 1, 2009, and July 31, 2012: 116 received CCRT and 54 received BioRT.
Complete response rates were similar in the SD-CCRT and BioRT groups (63.8% versus 59.3%; P = 0.807), and locoregional relapse rates were 18.1% and 13.0%, respectively (P = 0.400). The 3-year relapse-free survival rate was 65.8% in the SD-CCRT group and 65.5% in the BioRT group, respectively (P = 0.647). The 3-year overall survival rate was 78.5% in the SD-CCRT group and 70.9% in the BioRT group, respectively (P = 0.879). Hematologic side effects were significantly more frequent in the SD-CCRT than in the BioRT group. Mucositis frequency was similar.
Primary SD-CCRT and BioRT both showed good clinical response and survival. Hematologic toxicities were more frequent, but tolerable, in the SD-CCRT group. Both groups showed good compliance.
本研究旨在分析接受分剂量顺铂同步放化疗（SD - CCRT）或西妥昔单抗同步放疗（BioRT）治疗的局部晚期头颈癌（LAHNC）患者的生存率、临床反应、依从性及不良反应。
我们回顾性评估了2009年1月1日至2012年7月31日期间诊断的170例LAHNC患者：116例接受了CCRT，54例接受了BioRT。
SD - CCRT组和BioRT组的完全缓解率相似（63.8%对59.3%；P = 0.807），局部区域复发率分别为18.1%和13.0%（P = 0.400）。SD - CCRT组和BioRT组的3年无复发生存率分别为65.8%和65.5%（P = 0.647）。SD - CCRT组和BioRT组的3年总生存率分别为78.5%和70.9%（P = 0.879）。SD - CCRT组的血液学副作用明显比BioRT组更频繁。黏膜炎发生率相似。
原发性SD - CCRT和BioRT均显示出良好的临床反应和生存率。SD - CCRT组血液学毒性更频繁，但可耐受。两组均显示出良好的依从性。
